JIMCO (the Abdul Latif Jameel Investment Management Company) is the Jameel Family’s global investment arm, consolidating under one name an established Jameel Family tradition of investing in innovative ideas and businesses promising positive change that stretches back to, at least, the early 1980s. Today, JIMCO is an active global investor in innovative, early-stage and breakthrough ventures, business models and emergent technologies, aiming to positively shape the future of core industries driving the global economy.
These investments are diverse and embrace medical and healthcare industries, fintech, insurtech, electric vehicles and future mobility solutions, and the future of energy, amongst others, and are made in carefully selected and targeted funds and also in fledgling businesses, but all have a common focus in the pursuit of a more sustainable tomorrow.
JIMCO comprises a number of independent legal entities, there are three primary fund brands:
- The JIMCO Technology Fund – focusing on venture building, both through select, targeted funds and direct investments.
- The JIMCO Life Sciences Fund – focusing on both direct and fund investments in life sciences, biotech and health care, from pharmaceuticals, therapeutics, vaccines and diagnostics to cutting-edge medical device technologies and techniques, and
- The JIMCO Strategic Asset Fund – focusing on forward-thinking fund with a clear, aligned, long-term vision, with relevant sector specialization from sustainability initiatives, to drivers of global energy transformation towards renewable, sustainable and clean sources of power.
About Cambridge Epigenetix
Cambridge Epigenetix is revolutionizing sequencing by delivering new dimensions of information from DNA to see and treat disease earlier and transform life sciences and medicine. The commercial-stage company’s platform provides more information with greater efficiency at higher quality and lower cost than standard next generation DNA sequencing technology. Easily integrating into existing sequencers, the company’s products allow the user to see at-a-glance genomic and epigenetic information. This information can be used to detect, diagnose, treat and understand disease.
Based in Cambridge, UK, the company is founded by a pioneer in DNA sequencing intent on leading the next great leap forward in genomics.
Learn more: cambridge-epigenetix.com
Business Contact: firstname.lastname@example.org
Tony Plohoros email@example.com